Resmed Stock News

SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the KeyBanc Capital M

ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

ResMed's (RMD) robust international performance and an ongoing rebound in device sales instill investor confidence in the stock.

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 32nd Annual Healthcare

SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15, 2022, beginning at approximately 1:20 p.m. (Eastern Daylight Time) via webcast.

ResMed Inc (ASX:RMD) and this ASX healthcare share could be top options in the sector right now. Here''s what you need to know…

We believe that ResMed, a medical equipment company, currently appears to be an attractive pick over Ciena stock, a telecommunications networking equipment and software services company, with a simila

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

ResMed's (RMD) growing focus to expand in the high-growth international markets is an added upside.

ResMed Inc. found using ticker (RMD) now have 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 312 and 235 calculating the mean target price we have 268. With the stocks previous close at 249.91 this now indicates there is a potential upside of 7.2%. There is a 50 day moving average of 243 and the 200 day MA is 254.1. The market capitalisation for the company is $37,231m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets=RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $39,926m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.

IHI: A Standout Performer With Equally Strong Future Growth Prospects

The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. The post 3 Beaten-Down Growth Stocks With More Than 50% Upsi